Literature DB >> 9690329

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

A Lin1, G Kenis, S Bignotti, G J Tura, R De Jong, E Bosmans, R Pioli, C Altamura, S Scharpé, M Maes.   

Abstract

There is some evidence that the pathophysiology of schizophrenia is related to activation of the inflammatory response system (IRS), as indicated by increased serum concentrations of interleukin-6 (IL-6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and IL-2R and lower serum concentrations of CC16, an endogenous anti-inflammatory protein with immunosuppressive and anti-inflammatory effects. The aims of the present study were to examine serum CC16 in relation to IL-6, IL-6R and gp130, the IL-6 transducing signal protein, in schizophrenia and in treatment-resistant schizophrenia (TRS). Serum IL-6 and sIL-6R were significantly higher in medicated schizophrenic patients than in normal controls. Serum IL-6 was significantly higher in TRS than in normal volunteers, whereas schizophrenic patients without TRS showed intermediate values. Serum CC16 was significantly lower in schizophrenic patients with a positive family history for psychoses than in normal volunteers and patients without a positive family history. There was a significant inverse relationship between serum CC16 and serum IL-6 or sIL-6R in schizophrenic patients, but not in normal volunteers. The results suggest that the inflammatory response in schizophrenia, as indicated by increased serum IL-6 and sIL-6R, may be causally related to lower serum CC16 and that the latter might be a trait marker for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690329     DOI: 10.1016/s0920-9964(98)00034-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  72 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

2.  Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.

Authors:  Xueqin Song; Xiaoduo Fan; Xue Li; Wei Zhang; Jinsong Gao; Jingping Zhao; Amy Harrington; Douglas Ziedonis; Luxian Lv
Journal:  Psychopharmacology (Berl)       Date:  2013-12-14       Impact factor: 4.530

3.  From stress to psychosis: whom, how, when and why?

Authors:  V Mondelli
Journal:  Epidemiol Psychiatr Sci       Date:  2014-06-06       Impact factor: 6.892

4.  Immune System and Schizophrenia.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Curr Immunol Rev       Date:  2010-08

Review 5.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

Review 7.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

8.  Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders.

Authors:  Shyamalagauri Jadhav; Miriam L Greenberg
Journal:  Clin Lipidol       Date:  2014-11-01

9.  The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.

Authors:  X Fan; X Song; M Zhao; L F Jarskog; R Natarajan; N Shukair; O Freudenreich; D C Henderson; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2017-08-29       Impact factor: 6.392

Review 10.  Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms.

Authors:  Ryan J Van Lieshout; Lakshmi P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2008-09       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.